Median follow-up duration was 139.8 months and 29 patients (14.4%) had distant recurrence of cancer; 20 patients (19.8%) with high SP1 expression had tumor recurrence in contrast to only nine patients (8.9%) with low SP1 expression. The gene discussed is SP1; the disease is cancer.